VasoDynamics Ltd

VasoDynamics is a clinical-stage pharmaceutical development company based in Stevenage and London, UK. It specializes in creating patient-friendly, cost-effective medicines designed to prevent severe side effects induced by anticancer therapies, such as radiotherapy and chemotherapy. The company’s proprietary technology platform leverages differences between normal and cancerous vasculature to develop formulations aimed at protecting skin, mucosa, and hair. Its lead programs focus on preventing radiation-induced oral mucositis, radiation-induced dermatitis, and chemotherapy-induced alopecia.

These therapies are intended to improve the quality of life for cancer patients by preventing debilitating side effects that can be painful, traumatic, and treatment-limiting. By enabling patients to better tolerate standard anticancer regimens, VasoDynamics aims to enhance the efficacy of cancer treatments while offering potential cost savings to healthcare systems by reducing the complications associated with cancer therapy. The company is actively engaged in global regulatory processes, including consultations with the EMA, FDA, and UK MHRA, as it advances its product pipeline through clinical trials toward market approval.